Perspective Therapeutics Inc (CATX)

$3.43 +0.27 (8.54%)
Market Cap 213.58M
Revenue (ttm) 1.43M
Net Income (ttm) -46.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,252.45%
Debt to Equity Ratio 0.00
Volume 1,116,500
Avg Vol 1,808,228
Day's Range N/A - N/A
Shares Out 67.59M
Stochastic %K 57%
Beta 1.19
Analysts Strong Sell
Price Target $15.00

Latest News on CATX

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Jan 6, 2025, 8:00 AM EST - 11 days ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 23, 2024, 11:13 AM EST - 25 days ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Dec 20, 2024, 4:16 PM EST - 4 weeks ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 27, 2024, 7:00 AM EST - 7 weeks ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 21, 2024, 7:15 AM EST - 2 months ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 15, 2024, 4:08 PM EST - 2 months ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:05 PM EST - 2 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 29, 2024, 7:00 AM EDT - 2 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 23, 2024, 7:00 AM EDT - 3 months ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 16, 2024, 7:00 AM EDT - 3 months ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 12:05 PM EDT - 3 months ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 11, 2024, 8:30 AM EDT - 3 months ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 3 months ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 7, 2024, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 3:11 PM EDT - 3 months ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Oct 2, 2024, 12:10 PM EDT - 3 months ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 30, 2024, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Sep 5, 2024, 7:00 AM EDT - 4 months ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Aug 12, 2024, 4:05 PM EDT - 5 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Jul 30, 2024, 7:00 AM EDT - 6 months ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Jul 22, 2024, 7:00 AM EDT - 6 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Jun 12, 2024, 7:00 AM EDT - 7 months ago

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Jun 11, 2024, 7:00 AM EDT - 7 months ago

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Jun 10, 2024, 4:10 PM EDT - 7 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 24, 2024, 8:01 AM EDT - 8 months ago

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

May 20, 2024, 7:00 AM EDT - 8 months ago

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

May 15, 2024, 7:00 AM EDT - 8 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Perspective Therapeutics to Participate at Upcoming May Investor Conferences

May 3, 2024, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate at Upcoming May Investor Conferences

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

May 2, 2024, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs

Apr 30, 2024, 7:00 AM EDT - 9 months ago

Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

Apr 8, 2024, 8:00 AM EDT - 10 months ago

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Mar 28, 2024, 7:30 AM EDT - 10 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Perspective Therapeutics Announces $87.4 Million Private Placement

Mar 4, 2024, 9:45 AM EST - 11 months ago

Perspective Therapeutics Announces $87.4 Million Private Placement

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Feb 1, 2024, 8:00 AM EST - 1 year ago

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

Jan 22, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

Jan 18, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

Perspective Therapeutics Announces Proposed Public Offering

Jan 17, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Announces Proposed Public Offering

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

Jan 17, 2024, 8:00 AM EST - 1 year ago

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Jan 9, 2024, 8:00 AM EST - 1 year ago

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

Dec 7, 2023, 8:00 AM EST - 1 year ago

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Nov 14, 2023, 4:25 PM EST - 1 year ago

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma

Perspective Therapeutics' Cesium-131 Featured at the American Society for Radiation Oncology's Annual Conference

Oct 5, 2023, 4:05 PM EDT - 1 year ago

Perspective Therapeutics' Cesium-131 Featured at the American Society for Radiation Oncology's Annual Conference

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

Aug 30, 2023, 8:17 AM EDT - 1 year ago

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Aug 11, 2023, 8:05 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Aug 11, 2023, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment

Aug 9, 2023, 8:05 AM EDT - 1 year ago

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment

Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Jun 21, 2023, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates